Trial Search Results

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Bristol-Myers Squibb

Stanford Investigator(s):


  • Drug: Brivanib
  • Other: Brivanib Placebo
  • Procedure: TACE Therapy


Phase 3


For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

   - Patients with diagnosis of hepatocellular carcinoma

   - Cirrhotic status of Child-Pugh Class A or B with a score of 7

   - ECOG performance status of 0 or 1

   - Adequate hematologic, hepatic, and renal function

Exclusion criteria:

   - Prior use of any systemic anticancer chemotherapy, immunotherapy, investigational or
   molecular targeted agents for HCC

   - History of cardiac disease

   - Active and untreated hepatitis B

   - Inability to swallow tablets or untreated malabsorption syndrome

   - History of human immunodeficiency virus (HIV) infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting